Session Details

[27-07-am]Absorption, Controlled Release/Targeting, Pharmacotherapy (Oncology), Pharmacoepidemiology, Health Economics

Thu. Mar 27, 2025 8:30 AM - 9:42 AM JST
Thu. Mar 27, 2025 11:30 PM - 12:42 AM UTC
Room 7 (Fukuoka International Congress Center: 204 [2F])
Chair: Tadatoshi Tanino, Takashi Imanishi

[27-07-am01S]Prediction of Intestinal Permeability Using Machine Learning

○Reiji Negoya1, Atsushi Kambayashi1 (1. Faculty of Pharmaceutical Sciences, Tokyo University of Science)

[27-07-am02S]Effect of characteristics of STING agonist-loaded lipid nanoparticles on cancer immune responses

○Takumi Nagaoki1, Rikito Endo1, Tomoki Ueda1, Natsumi Shima1, Yusuke Sato1, Hideyoshi Harashima1, Takashi Nakamura1,2 (1. Fac. Pharm. Sci., Hokkaido Univ., 2. Fac. Pharm. Sci., Kanazawa Univ.)

[27-07-am03S]Relationship between venetoclax blood levels and efficacy and drug-drug interactions affecting blood levels.

○Ayaka Kai1, Masao Hagihara2, Tomiyuki Sugi1,3 (1. Meiji Pharm Univ, 2. Department of Hematology, Eiju General Hospital, 3. Department of Pharmacy, Eiju General Hospital)

[27-07-am04S]Comparison of risk of serious infection between self-injection and non-self-injection under the treatment with biologics in patients with rheumatoid arthritis

○Shingo Akutsu1, Kazuhiko Takahata1, Ryoko Sakai1, Manabu Akazawa1 (1. Meiji pharmaceutical University)

[27-07-am05S]Medical costs for patients with large vessel vasculitis after approval for Tocilizumab in Japan

○Miyuki Jinnouchi1, Sari Horiuchi1, Yukumitsu Kudo1, Kotaro Kawano1, Takahiko Sugihara2, Ryosuke Kumazawa1, Ryoko Sakai1, Manabu Akazawa1 (1. Meiji pharmaceutical University, 2. Toho University)

[27-07-am06S]Medications associated with serious infections in patients with giant cell arteritis and Takayasu arteritis

○Yukumitsu Kudo1, Sari Horiuchi1, Miyuki Jinnouchi1, Kotaro Kawano1, Takahiko Sugihara2, Ryosuke Kumazawa1, Ryoko Sakai1, Manabu Akazawa1 (1. Meiji Pharmaceutical University, 2. Toho University)